This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hollis, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hollis, R. J.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2003, p. 1440-1446, Vol. 41, No. 4
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.4.1440-1446.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001

M. A. Pfaller,1,2* D. J. Diekema,1,3 S. A. Messer,1 L. Boyken,1 and R. J. Hollis1

Departments of Pathology,1 Medicine,3 Epidemiology, Roy J. and Lucille A. Carver College of Medicine and College of Public Health, University of Iowa, Iowa City, Iowa 522422

Received 11 October 2002/ Returned for modification 5 December 2002/ Accepted 22 December 2002

The ARTEMIS Global Antifungal Susceptibility Program (ARTEMIS Program) was initiated in 2001 to provide focused surveillance of the activities of fluconazole and voriconazole against Candida spp. isolated from blood and other normally sterile sites. A total of 1,586 episodes of infection were detected at 61 international study sites. Overall, 57.7% of the infections were due to Candida albicans, followed by C. glabrata (14.8%), C. parapsilosis (12.5%), C. tropicalis (9.4%), C. krusei (2.7%), and C. lusitaniae (1.5%). Isolates of C. albicans, C. parapsilosis, and C. tropicalis were all highly susceptible to fluconazole (for 99% of the isolates the MICs were <=8 µg/ml). Likewise, 99 to 100% of these species were inhibited by <=1 µg of voriconazole per ml. Voriconazole was also active against C. glabrata (93% of the isolates were susceptible [MICs <= 1 µg/ml]) and C. krusei (100% of the isolates were susceptible). The agar-based Etest and disk diffusion methods performed well for the testing of both fluconazole and voriconazole compared to the broth microdilution MIC reference method. These observations establish the continued importance of C. albicans as a pathogen and the sustained activity of fluconazole and the broad spectrum of activity of voriconazole and will serve as the first-year benchmark for the ARTEMIS Program. Continued surveillance and refinement of broth- and agar-based test methods will help to identify susceptibility trends and improve the laboratory capability for antifungal susceptibility testing.

* Corresponding author. Mailing address: Molecular Epidemiology & Fungus Testing Laboratory, Departments of Pathology and Epidemiology, C606 GH, University of Iowa College of Medicine and College of Public Health, Iowa City, IA 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.

Journal of Clinical Microbiology, April 2003, p. 1440-1446, Vol. 41, No. 4
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.4.1440-1446.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Mandras, N., Tullio, V., Allizond, V., Scalas, D., Banche, G., Roana, J., Robbiano, F., Fucale, G., Malabaila, A., Cuffini, A. M., Carlone, N. (2009). In Vitro Activities of Fluconazole and Voriconazole against Clinical Isolates of Candida spp. Determined by Disk Diffusion Testing in Turin, Italy. Antimicrob. Agents Chemother. 53: 1657-1659 [Abstract] [Full Text]  
  • Lockhart, S. R., Messer, S. A., Gherna, M., Bishop, J. A., Merz, W. G., Pfaller, M. A., Diekema, D. J. (2009). Identification of Candida nivariensis and Candida bracarensis in a Large Global Collection of Candida glabrata Isolates: Comparison to the Literature. J. Clin. Microbiol. 47: 1216-1217 [Abstract] [Full Text]  
  • Lockhart, S. R., Messer, S. A., Pfaller, M. A., Diekema, D. J. (2009). Identification and Susceptibility Profile of Candida fermentati from a Worldwide Collection of Candida guilliermondii Clinical Isolates. J. Clin. Microbiol. 47: 242-244 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2008). Validation of 24-Hour Fluconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Results from a Global Candida Antifungal Surveillance Program. J. Clin. Microbiol. 46: 3585-3590 [Abstract] [Full Text]  
  • Trofa, D., Gacser, A., Nosanchuk, J. D. (2008). Candida parapsilosis, an Emerging Fungal Pathogen. Clin. Microbiol. Rev. 21: 606-625 [Abstract] [Full Text]  
  • Lockhart, S. R., Messer, S. A., Pfaller, M. A., Diekema, D. J. (2008). Geographic Distribution and Antifungal Susceptibility of the Newly Described Species Candida orthopsilosis and Candida metapsilosis in Comparison to the Closely Related Species Candida parapsilosis. J. Clin. Microbiol. 46: 2659-2664 [Abstract] [Full Text]  
  • Diekema, D. J., Messer, S. A., Hollis, R. J., Boyken, L. B., Tendolkar, S., Kroeger, J., Pfaller, M. A. (2007). Evaluation of Etest and Disk Diffusion Methods Compared with Broth Microdilution Antifungal Susceptibility Testing of Clinical Isolates of Candida spp. against Posaconazole. J. Clin. Microbiol. 45: 1974-1977 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Canton, E., Gibbs, D., Wang, A. (2007). Correlation of Neo-Sensitabs Tablet Diffusion Assay Results on Three Different Agar Media with CLSI Broth Microdilution M27-A2 and Disk Diffusion M44-A Results for Testing Susceptibilities of Candida spp. and Cryptococcus neoformans to Amphotericin B, Caspofungin, Fluconazole, Itraconazole, and Voriconazole. J. Clin. Microbiol. 45: 858-864 [Abstract] [Full Text]  
  • Schabereiter-Gurtner, C., Selitsch, B., Rotter, M. L., Hirschl, A. M., Willinger, B. (2007). Development of Novel Real-Time PCR Assays for Detection and Differentiation of Eleven Medically Important Aspergillus and Candida Species in Clinical Specimens. J. Clin. Microbiol. 45: 906-914 [Abstract] [Full Text]  
  • Mokaddas, E. M., Al-Sweih, N. A., Khan, Z. U. (2007). Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 56: 255-259 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2007). Use of Fluconazole as a Surrogate Marker To Predict Susceptibility and Resistance to Voriconazole among 13,338 Clinical Isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-Recommended Broth Microdilution Methods. J. Clin. Microbiol. 45: 70-75 [Abstract] [Full Text]  
  • Wang, J.-S., Yang, Y.-L., Wu, C.-J., Ouyang, K. J., Tseng, K.-Y., Chen, C.-G., Wang, H., Lo, H.-J. (2006). The DNA-binding domain of CaNdt80p is required to activate CDR1 involved in drug resistance in Candida albicans.. J Med Microbiol 55: 1403-1411 [Abstract] [Full Text]  
  • Panackal, A. A., Gribskov, J. L., Staab, J. F., Kirby, K. A., Rinaldi, M., Marr, K. A. (2006). Clinical Significance of Azole Antifungal Drug Cross-Resistance in Candida glabrata.. J. Clin. Microbiol. 44: 1740-1743 [Abstract] [Full Text]  
  • Messer, S. A., Jones, R. N., Fritsche, T. R. (2006). International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003).. J. Clin. Microbiol. 44: 1782-1787 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Sheehan, D. J. (2006). Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. Clin. Microbiol. Rev. 19: 435-447 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A, Odds, F. C., Rinaldi, M. G., Sheehan, D. J., Troke, P., Walsh, T. J., Warnock, D. W. (2006). Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints.. J. Clin. Microbiol. 44: 819-826 [Abstract] [Full Text]  
  • Golan, Y., Wolf, M. P., Pauker, S. G., Wong, J. B., Hadley, S. (2005). Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness Analysis. ANN INTERN MED 143: 857-869 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., Gibbs, D. L., the Global Antifungal Surveillance Group, (2005). Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing. J. Clin. Microbiol. 43: 5848-5859 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Messer, S. A., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2005). Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 43: 5208-5213 [Abstract] [Full Text]  
  • Sarvikivi, E., Lyytikainen, O., Soll, D. R., Pujol, C., Pfaller, M. A., Richardson, M., Koukila-Kahkola, P., Luukkainen, P., Saxen, H. (2005). Emergence of Fluconazole Resistance in a Candida parapsilosis Strain That Caused Infections in a Neonatal Intensive Care Unit. J. Clin. Microbiol. 43: 2729-2735 [Abstract] [Full Text]  
  • Richter, S. S., Galask, R. P., Messer, S. A., Hollis, R. J., Diekema, D. J., Pfaller, M. A. (2005). Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases. J. Clin. Microbiol. 43: 2155-2162 [Abstract] [Full Text]  
  • Balashov, S. V., Gardiner, R., Park, S., Perlin, D. S. (2005). Rapid, High-Throughput, Multiplex, Real-Time PCR for Identification of Mutations in the cyp51A Gene of Aspergillus fumigatus That Confer Resistance to Itraconazole. J. Clin. Microbiol. 43: 214-222 [Abstract] [Full Text]  
  • Chen, C.-G., Yang, Y.-L., Shih, H.-I, Su, C.-L., Lo, H.-J. (2004). CaNdt80 Is Involved in Drug Resistance in Candida albicans by Regulating CDR1. Antimicrob. Agents Chemother. 48: 4505-4512 [Abstract] [Full Text]  
  • Weig, M., Jansch, L., Gross, U., De Koster, C. G., Klis, F. M., De Groot, P. W. J. (2004). Systematic identification in silico of covalently bound cell wall proteins and analysis of protein-polysaccharide linkages of the human pathogen Candida glabrata. Microbiology 150: 3129-3144 [Abstract] [Full Text]  
  • Pfaller, M. A., Hazen, K. C., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2004). Comparison of Results of Fluconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 42: 3607-3612 [Abstract] [Full Text]  
  • Serrano, M. C., Ramirez, M., Morilla, D., Valverde, A., Chavez, M., Espinel-Ingroff, A., Claro, R., Fernandez, A., Almeida, C., Martin-Mazuelos, E. (2004). A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.. J Antimicrob Chemother 53: 739-742 [Abstract] [Full Text]  
  • Pfaller, M. A., Barry, A., Bille, J., Brown, S., Ellis, D., Meis, J. F., Rennie, R., Rinaldi, M., Rogers, T., Traczewski, M. (2004). Quality Control Limits for Voriconazole Disk Susceptibility Tests on Mueller-Hinton Agar with Glucose and Methylene Blue. J. Clin. Microbiol. 42: 1716-1718 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Messer, S. A., Hollis, R. J., Diekema, D. J. (2004). Stability of Mueller-Hinton Agar Supplemented with Glucose and Methylene Blue for Disk Diffusion Testing of Fluconazole and Voriconazole. J. Clin. Microbiol. 42: 1288-1289 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2004). Evaluation of the NCCLS M44-P Disk Diffusion Method for Determining Susceptibilities of 276 Clinical Isolates of Cryptococcus neoformans to Fluconazole. J. Clin. Microbiol. 42: 380-383 [Abstract] [Full Text]  
  • Girmenia, C., Pizzarelli, G., D'Antonio, D., Cristini, F., Martino, P. (2003). In Vitro Susceptibility Testing of Geotrichum capitatum: Comparison of the E-Test, Disk Diffusion, and Sensititre Colorimetric Methods with the NCCLS M27-A2 Broth Microdilution Reference Method. Antimicrob. Agents Chemother. 47: 3985-3988 [Abstract] [Full Text]  
  • Hazen, K. C., Baron, E. J., Colombo, A. L., Girmenia, C., Sanchez-Sousa, A., del Palacio, A., de Bedout, C., Gibbs, D. L. (2003). Comparison of the Susceptibilities of Candida spp. to Fluconazole and Voriconazole in a 4-Year Global Evaluation Using Disk Diffusion. J. Clin. Microbiol. 41: 5623-5632 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»